EGFR and cancer: Further work should explore the extent to which EGFR and WNT receptors (Frizzled and LRP5/6) each transmit the effect of ZNRF3/RNF43 deactivation at different cancer stages and investigate the efficacy of blocking both EGFR and WNT signaling in treatment of ZNRF3/RNF43-deactivated tumors.